Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker

[1]  J. Nilsson,et al.  Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome , 2020, Scandinavian journal of gastroenterology.

[2]  J. Nilsson,et al.  Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma , 2020, Scandinavian journal of gastroenterology.

[3]  R. Tollenaar,et al.  Tumor stroma as contributing factor in the lymph node metastases process? , 2019, Oncotarget.

[4]  X. Hao,et al.  Integrated analysis of microfibrillar-associated proteins reveals MFAP4 as a novel biomarker in human cancers. , 2019, Epigenomics.

[5]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[6]  S. Qiu,et al.  S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma , 2018, Molecular carcinogenesis.

[7]  H. Järveläinen,et al.  Decorin‐mediated oncosuppression – a potential future adjuvant therapy for human epithelial cancers , 2018, British journal of pharmacology.

[8]  J. Svasti,et al.  NOTCH1 regulates the viability of cholangiocarcinoma cells via 14-3-3 theta , 2018, Journal of Cell Communication and Signaling.

[9]  Thomas L. Fillmore,et al.  Residual tissue repositories as a resource for population-based cancer proteomic studies , 2018, Clinical Proteomics.

[10]  S. Cai,et al.  Osteoglycin-induced VEGF Inhibition Enhances T Lymphocytes Infiltrating in Colorectal Cancer , 2018, EBioMedicine.

[11]  C. Pairojkul,et al.  Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[12]  S. Cai,et al.  Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway , 2018, Journal of experimental & clinical cancer research : CR.

[13]  A. Gazdar,et al.  Dysregulation of fibulin-5 and matrix metalloproteases in epithelial ovarian cancer , 2018, Oncotarget.

[14]  G. Gores,et al.  Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.

[15]  Thawfeek M. Varusai,et al.  The Reactome Pathway Knowledgebase , 2017, Nucleic acids research.

[16]  F. Domann,et al.  Extracellular superoxide dismutase and its role in cancer. , 2017, Free radical biology & medicine.

[17]  Atul J Butte,et al.  Comprehensive analysis of normal adjacent to tumor transcriptomes , 2017, Nature Communications.

[18]  Qingrui Yang,et al.  Role of collagen triple helix repeat containing-1 in tumor and inflammatory diseases. , 2017, Journal of cancer research and therapeutics.

[19]  C. Glorieux,et al.  Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach , 2017, Biological chemistry.

[20]  A. Zhu,et al.  New Horizons for Precision Medicine in Biliary Tract Cancers. , 2017, Cancer discovery.

[21]  B. Garcia,et al.  Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers , 2017, Science Translational Medicine.

[22]  P. Yu,et al.  Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma , 2017, Oncotarget.

[23]  K. Sawanyawisuth,et al.  Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis. , 2017, Histology and histopathology.

[24]  M. Franchi,et al.  Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition , 2017, Scientific Reports.

[25]  Yasunori Sato,et al.  An S100P-positive biliary epithelial field is a preinvasive intraepithelial neoplasm in nodular-sclerosing cholangiocarcinoma. , 2017, Human pathology.

[26]  K. Hirata,et al.  Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer , 2017, Oncotarget.

[27]  N. Khuntikeo,et al.  Imbalanced adaptive responses associated with microsatellite instability in cholangiocarcinoma , 2016, Oncology letters.

[28]  Anushya Muruganujan,et al.  PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements , 2016, Nucleic Acids Res..

[29]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[30]  Mathias Müller,et al.  The good and the bad faces of STAT1 in solid tumours. , 2017, Cytokine.

[31]  B. Bozóky,et al.  Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification , 2016, PloS one.

[32]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[33]  Lin He,et al.  Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better "housekeeper" , 2016, Oncotarget.

[34]  M. Lai,et al.  Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases , 2016, PloS one.

[35]  Adele Bourmaud,et al.  Parallel reaction monitoring using quadrupole‐Orbitrap mass spectrometer: Principle and applications , 2016, Proteomics.

[36]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[37]  Y. Li,et al.  The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma , 2016, PloS one.

[38]  B. Sitek,et al.  Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells* , 2016, Molecular & Cellular Proteomics.

[39]  D. Stern,et al.  Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival – Evidence from TCGA Pan-Cancer Data , 2016, Scientific Reports.

[40]  X-M Jia,et al.  Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets , 2015, Cancer Gene Therapy.

[41]  G. Marko‐Varga,et al.  Cholangiocarcinoma – current classification and challenges towards personalised medicine , 2016, Scandinavian journal of gastroenterology.

[42]  B. Sitek,et al.  Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions , 2016, Journal of Clinical Pathology.

[43]  R. Schmuck,et al.  Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity , 2015, Cancer medicine.

[44]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[45]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[46]  Stefani N. Thomas,et al.  Advances in mass spectrometry-based clinical biomarker discovery , 2016, Clinical Proteomics.

[47]  N. Rauniyar,et al.  Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry , 2015, International journal of molecular sciences.

[48]  Toshihide Nishimura,et al.  Mass spectrometry‐based proteomic analysis of formalin‐fixed paraffin‐embedded extrahepatic cholangiocarcinoma , 2015, Journal of hepato-biliary-pancreatic sciences.

[49]  T. Shibata,et al.  Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma , 2015, Molecular Cancer Therapeutics.

[50]  Peter Hoffmann,et al.  Proteomic developments in the analysis of formalin-fixed tissue. , 2015, Biochimica et biophysica acta.

[51]  Jun-Tao Ji,et al.  RNA sequencing reveals differentially expressed genes as potential diagnostic and prognostic indicators of gallbladder carcinoma , 2015, Oncotarget.

[52]  A. Bergquist,et al.  Epidemiology of cholangiocarcinoma. , 2015, Best practice & research. Clinical gastroenterology.

[53]  Juancarlos Chan,et al.  Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..

[54]  Damon H. May,et al.  Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma , 2014, Laboratory Investigation.

[55]  J. Xu,et al.  Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. , 2014, Cancer letters.

[56]  T. Kyriakides,et al.  Thrombospondin-2 and extracellular matrix assembly. , 2014, Biochimica et biophysica acta.

[57]  B. Sitek,et al.  Identification of Novel Biomarker Candidates for the Immunohistochemical Diagnosis of Cholangiocellular Carcinoma , 2014, Molecular & Cellular Proteomics.

[58]  Nataliya Razumilava,et al.  Cholangiocarcinoma , 2014, The Lancet.

[59]  R. Bergan,et al.  Diminished expression of h2-calponin in prostate cancer cells promotes cell proliferation, migration and the dependence of cell adhesion on substrate stiffness , 2014, FEBS open bio.

[60]  G. Gores,et al.  Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting , 2014, Hepatology.

[61]  Christoph H. Borchers,et al.  Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays , 2014, Molecular oncology.

[62]  P. Lescuyer,et al.  An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis. , 2014, Biochimica et biophysica acta.

[63]  V. Paradis,et al.  Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry , 2014, Proteomics.

[64]  Jing Chen,et al.  Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment , 2014, World Journal of Surgical Oncology.

[65]  Alexander Scherl,et al.  Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues , 2014, Proteomics.

[66]  Guangming Huang,et al.  Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro , 2014, Tumor Biology.

[67]  Yasunori Sato,et al.  Clinicopathological significance of S100 protein expression in cholangiocarcinoma , 2013, Journal of gastroenterology and hepatology.

[68]  C. Peng,et al.  A Prospective Proteomic-Based Study for Identifying Potential Biomarkers for the Diagnosis of Cholangiocarcinoma , 2013, Journal of Gastrointestinal Surgery.

[69]  L. Fabris,et al.  Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. , 2013, Translational gastrointestinal cancer.

[70]  Masakazu Yamamoto,et al.  Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma. , 2013, Journal of proteomics.

[71]  F. Soares,et al.  Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia. , 2013, Experimental and molecular pathology.

[72]  E. Chevet,et al.  Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development , 2013, Oncogene.

[73]  P. Selby,et al.  Proteomic analysis of formalin‐fixed paraffin‐embedded renal tissue samples by label‐free MS: Assessment of overall technical variability and the impact of block age , 2013, Proteomics. Clinical applications.

[74]  G. Gores,et al.  Classification, diagnosis, and management of cholangiocarcinoma. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[75]  M. Wang,et al.  Comparative Proteomic Profiling of Human Bile Reveals SSP411 as a Novel Biomarker of Cholangiocarcinoma , 2012, PloS one.

[76]  B. Domon,et al.  Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.

[77]  Derek J. Bailey,et al.  Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.

[78]  K. Uzawa,et al.  Dermatopontin: A potential predictor for metastasis of human oral cancer , 2012, International journal of cancer.

[79]  C. Wongkham,et al.  Inflammation-induced protein carbonylation contributes to poor prognosis for cholangiocarcinoma. , 2012, Free radical biology & medicine.

[80]  Michael J. MacCoss,et al.  Platform-independent and Label-free Quantitation of Proteomic Data Using MS1 Extracted Ion Chromatograms in Skyline , 2012, Molecular & Cellular Proteomics.

[81]  N. Hiraoka,et al.  Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. , 2012, Journal of proteomics.

[82]  Martin Kircher,et al.  Deep proteome and transcriptome mapping of a human cancer cell line , 2011, Molecular systems biology.

[83]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[84]  S. Lepreux,et al.  Proteomic Analysis of Differentially Expressed Proteins in Peripheral Cholangiocarcinoma , 2011, Cancer Microenvironment.

[85]  Myung Ah Lee,et al.  Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer , 2010, BMC Cancer.

[86]  R. Iozzo,et al.  Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine‐rich proteoglycans , 2010, The FEBS journal.

[87]  John R Yates,et al.  Mass spectrometry in high-throughput proteomics: ready for the big time , 2010, Nature Methods.

[88]  Didier Samuel,et al.  Identification of Cellular Targets in Human Intrahepatic Cholangiocarcinoma Using Laser Microdissection and Accurate Mass and Time Tag Proteomics* , 2010, Molecular & Cellular Proteomics.

[89]  M. Miwa,et al.  Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. , 2010, World journal of gastroenterology.

[90]  川瀬 寛.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues , 2010 .

[91]  Y. Abiko,et al.  Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker , 2010, Molecular Cancer.

[92]  D. Berger,et al.  Tumor-derived pancreatic stellate cells promote pancreatic cancer cell invasion through release of thrombospondin-2. , 2009, The Journal of surgical research.

[93]  Masato Nakamura,et al.  Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. , 2009, Oncology reports.

[94]  F. Inagaki,et al.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues. , 2009, Journal of proteome research.

[95]  Yuman Fong,et al.  Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract , 2008, Journal of experimental & clinical cancer research : CR.

[96]  B. Balgley,et al.  Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues. , 2009, Journal of proteome research.

[97]  Troels Z. Kristiansen,et al.  Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. , 2008, Journal of proteome research.

[98]  O. Volpert,et al.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. , 2008, Current drug targets.

[99]  Masato Nakamura,et al.  Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells. , 2008, Molecular medicine reports.

[100]  J. Lawler,et al.  Thrombospondins in cancer. , 2008, Cellular and molecular life sciences : CMLS.

[101]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[102]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[103]  V. Herlea,et al.  The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. , 2006, Journal of gastrointestinal and liver diseases : JGLD.

[104]  O. Okamoto,et al.  Dermatopontin, a Novel Player in the Biology of the Extracellular Matrix , 2006, Connective tissue research.

[105]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[106]  F. Bertucci,et al.  Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. , 2002, The American journal of pathology.

[107]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[108]  Erwin G. Van Meir,et al.  Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.